#Best Neurology Treatment in Mauritius

[medserg1501]

Best Cardiology Treatment in Mauritius

The best cardiology treatment in Mauritius is accessible through hospitals equipped with advanced diagnostic tools and highly qualified cardiologists specializing in a range of cardiac conditions. Mauritius offers excellent heart care services, including treatment for coronary artery disease, heart valve issues, and arrhythmias, through a combination of cutting-edge technology and expert medical teams. For complex treatments such as open-heart surgeries, patients may explore medical tourism options, including partnerships with Indian hospitals, for cost-effective yet high-quality care. MedSerg facilitates these connections, ensuring Mauritius patients receive specialized cardiology treatment.

[medserg0929]

Unlocking World-Class Neurology Treatment in India: A Lifeline for Mauritius Patients with Medserg

Are you or a loved one in Mauritius seeking advanced neurology treatments? 🌍✨ Look no further than India, a hub for cutting-edge neurological care, now accessible to you with the help of Medserg!

Why India? 🇮🇳

India boasts some of the world’s top neurology specialists and state-of-the-art medical facilities. From groundbreaking treatments for epilepsy and Parkinson's disease to advanced neuro-oncology and stroke care, Indian hospitals offer a spectrum of services that are both innovative and affordable.

How Medserg Makes It Easy:

Personalized Consultation 🩺: Medserg provides tailored consultations to understand your specific needs and connect you with the right specialists in India.

Seamless Coordination 🌐: From scheduling appointments to arranging travel and accommodation, Medserg handles all the logistics, ensuring a smooth journey for you and your family.

High-Quality Care 💉: Medserg collaborates with top-tier Indian hospitals renowned for their expertise and patient-centered care, ensuring you receive the best possible treatment.

Affordable Solutions 💸: Enjoy world-class medical care without the hefty price tag. Medserg helps you navigate cost-effective treatment options without compromising quality.

Why Choose Medserg?

Medserg acts as your bridge to India’s premier neurological care, making the process hassle-free and personalized. They prioritize your health and comfort, ensuring you have access to the best medical professionals and facilities.

Take the First Step Towards Better Health

If you’re in Mauritius and looking for top-notch neurology treatments, let Medserg guide you to the best India has to offer. 🌟

For more information and to start your journey towards better health, visit Medserg website or contact them directly. Your path to recovery is just a click away!

[enzaime-blog]

Jack's recovery story from brain tumor

New Story has been published on https://enzaime.com/jacks-recovery-story-brain-tumor/

Jack's recovery story from brain tumor

Rallying Around ‘Jack’ – Buying Time for 11-Year-Old Who Touched the Hearts of His Care Team

He melts hearts with his infectious smile, cheerful attitude and frequent magic tricks.

But the slogan on Haonan Jiang’s T-shirt, which reads “Tough as Nails,” is a more accurate summation of his spirit, and the fight he and his family have been waging.

The 11-year-old from Beijing, China, prefers to be called “Jack.” He is suffering from what is known as an anaplastic astrocytoma, a grade 3 malignant tumor, according to his doctors at Mayo Clinic. The typical survival rate after diagnosis is one to three years.

Jack’s parents, Ben and Lili Jiang, had promised him a trip to see America when he finished primary school. But instead of sightseeing, their focus is now on Jack and doing anything possible to stop, or at least slow, his deteriorating and deadly condition.

Very little pain, and a sign of things to come

The first hint of trouble came last February. After a shower, Jack told his father that his right leg felt the heat from the shower differently from the left one. If Jack turned the water very hot, he didn’t feel any pain in his right leg. He also noted that if he squeezed his leg, there was very little sensation.

By March, Jack’s left leg began to lose strength. Then he lost the ability to feel both legs. He had to work hard to walk, had a halting gait, and used his hands to lift his legs to climb stairs. “A thought flashed in my mind, something is not okay with my son,” says Ben.

Shortly thereafter, Jack was admitted to a Beijing children’s hospital. He received three MRI scans over the span of a week, but the doctors told them there wasn’t much they could do. “It really hurt our hearts, but we didn’t give up,” says Ben. With the help of friends, he had Jack seen at five other top hospitals in Beijing.

Based on the MRI scans, doctors said they believed that Jack needed surgery for a cancerous tumor on his spine. He was still able to walk on his own, so doctors advised against what would be a risky procedure.

“It was very heartbreaking, and as a parent I could not accept that,” says Ben. “My son played all sports, excelled in school, I needed to do everything I could to give my son another chance.”

Friends in America willing to help

Jack’s parents asked their doctor about options abroad, but he wasn’t hopeful. They weren’t sure what to do next. Then Ben read a story on the Internet about a man with an illness similar to Jack’s who traveled from China to America for a successful treatment. When Ben learned that the man had been misdiagnosed, it gave him hope.

Ben recalls begging a Beijing hospital’s administrators to release Jack’s MRI records in a format required by U.S. hospitals.

The family had no friends to help them in the U.S. But they had recently vacationed on Mauritius, a small island off the Coast of Africa in the Indian Ocean, where they met a Chinese woman from America, and Lili had saved her phone number. They called and asked the woman about possible friends in the Boston area. She couldn’t help there, but she mentioned that she lives in Rochester, Minnesota, close to Mayo Clinic.

“I didn’t know anyone in America, yet I met someone who lived near Mayo Clinic. It’s like God arranged everything,” says Ben. “I told my wife this is a sign of what we’re going to do.”

Thanks to Ben’s travel promise to Jack, the process of securing a travel visa was already underway. They bought tickets for a flight to the U.S. the day after their travel visa arrived.

After arriving in Rochester in May, the family went to church with their friend. There they met new friends who listened to the family’s story and made sure that Jack’s case came to the attention of Mayo Clinic doctors.

He was admitted to Mayo Clinic Children’s Center, and after a biopsy of his spinal cord tumor was performed in late May, he was given the diagnosis of anaplastic astrocytoma.

Jack’s case is unusual in at least a few respects according to Nadia Laack, M.D., a pediatric radiation oncologist at Mayo Clinic. “They are rare tumors to begin with,” says Dr. Laack. And when they are found, she says, “95 percent of them are found in the brain.”

The location of the tumor left the medical team with few options.

Jack’s family and his doctors were not ready to give up, however. Ben recalls his social worker asking them why they had come to America. “Hope,” he answered. “If there is one country that can heal my son, it’s America.”

Rallying around the patient and family

Jack’s doctors thought he might benefit from radiation therapy. They wanted to slow down the rate of neurologic deterioration due to the progression of the tumor and improve the quality of his life.

By the time he was admitted to the Inpatient Rehabilitation Unit on the Saint Marys campus, Jack had lost the ability to use the lower half of his body. His father was carrying him to and from bed, so he could go to the bathroom, bathe and eat.

While Jack was receiving therapy on the rehabilitation unit, nurses gathered donated supplies for Jack’s family, and his physical therapist was able to get him a wheelchair. With no insurance, no funds other than personal savings, and the family’s decision to put their home up for sale, Jack’s team ensured he got the care he needed.

“The needs of the patient come first,” says Julia Iafrate, D.O., a resident in Physical Medicine and Rehabilitation. “So we made it happen. A number of providers acted together to make Jack’s needs come first.”

“The way the team brought their expertise and compassion to advocate for Jack just made me proud and grateful to work at Mayo,” says Sherilyn Driscoll, M.D., pediatric medical director, Mayo Clinic Physical Medicine and Rehabilitation. “His team helped make the difference between a sick boy lying in bed and an independent boy joyfully participating in life around him.”

Jack was able to join his family at the Ronald McDonald House in mid-June.

Progress, precious time and a superhero

Doctors designed a four-week course of radiation therapy specifically for Jack, so he could be well enough to return home to China by in August.

“We had very limited options. The goal is really to have tumor control, not a cure. That’s the nature of the disease,” says Mayo Clinic Pediatric Oncologist Amulya NageswaraRao, M.B.B.S.

“We’re buying time, only months really,” adds Dr. Iafrate. “But for an 11-year old child, that has all the meaning in the world for his family. That’s why we rallied so hard – to get him a few good months before he further declines.”

Ben was touched by the extraordinary effort. “From the doctors to the nurses, everyone treats my son and my family as a human being,” he says. “It makes me cry. It makes me cry a lot.”

When Jack first arrived in Rochester, he told his therapists his goal was to be able to walk to school again. He still needs his wheelchair, but since starting radiation treatments that are shrinking his tumor, some movement is returning to his right side, and he can move his leg.

Steroids have helped his appetite to return and he is slowly gaining weight. Jack says he loves his mother’s cooking. And French fries.

Along with video games, Jack is a big fan of Hollywood action movies and wants to be an actor. Hugh Jackman and Chris Evans are on his shortlist to meet. Thanks to the generosity of a Mayo Clinic patient, Jack got his wish.

Jack and his family were to fly to Berlin on their way home to China in mid-August. During a stop there, they visited a film production set and met actor Chris Evans, who plays Captain America. The crew was finishing up the final scenes for the next Marvel Comics movie.

“Awesome,” is how Jack summed up the news when he learned that he would meet one of his heroes.

It’s clear Jack and his family are heroes to his care team who are impressed by their “do everything, do anything” attitude to overcome financial, distance and language barriers.

“When someone feels they trust you, and you are their best hope, it’s hard not to be moved by that,” says Dr. Laack. Dr. Iafrate adds, “I don’t have children yet, but if and when I do, I want a ‘Jack.’ This child will be in my thoughts forever.”

Dr. Iafrate recently chatted with Ben, and told him, “Your family has touched the hearts of many people here. We love Jack. Thank you for being part of our lives.”

The feeling is mutual.

“No one would understand how lucky I feel for my son,” says Ben. “The doctors at Mayo Clinic are really angels whom God sent down to earth. Everyone helps the patients, thinking of many things that we didn’t think of as parents, and they are very happy to do so. That’s really amazing! I wish every doctor could be like Mayo’s one day in China.”

[nedsecondline]

US Lags Far Behind in Banning Dental Health Hazard

Example of mercury use in the healthcare sector. From left to right: Mercury Sphygmomanometer, Dental Amalgam and a Fever Thermometer. Credit: UNDP

By Thalif Deen UNITED NATIONS, Jul 31 2017 (IPS)

The United States is lagging far behind its Western allies – and perhaps most of the key developing countries – in refusing to act decisively to end a longstanding health and environmental hazard: the use of mercury in dentistry.

The 28-member European Union (EU), with an estimated population of over 510 million people, recently announced its decision to ban amalgam use in children under age 15, pregnant women, and breastfeeding mothers. The ban comes into effect July 2018.

“In sharp contrast, the U.S. government has done nothing to protect these vulnerable populations from exposure to amalgam’s mercury,” says a petition filed by Consumers for Dental Choice (CDC), which has been vigorously campaigning for mercury-free dentistry, since its founding back in 1996.

In Norway and Sweden, dental amalgam is no longer in use, while it is being phased out in Japan, Finland and the Netherlands. In Mauritius and EU nations, it is banned from use on children. Denmark uses dental amalgam for only 5% of restorations and Germany for 10% of restorations.

In Bangladesh, it is to be phased out in 2018, and in India, there is a dental school requirement of eliminating amalgam in favour of alternatives.

In Nigeria, the government has printed and distributed consumer-information brochures while the government of Canada has recommended that all dentists stop its use in children and pregnant women — and those with kidney disorders.

Dental amalgam has been described as a dental filling material used to fill cavities caused by tooth decay. And it is a mixture of metals, consisting of liquid (elemental) mercury and a powdered alloy composed of silver, tin, and copper.

In its petition, addressed to the FDA Commissioner, CDC says the United States – one of the only developed nation with no warnings or restrictions on the use of dental amalgam in children – is the outlier.

“Why are other countries protecting their children while the FDA lets American children be exposed to dental mercury? In order to catch up with other developed nations, the Commissioner must amend FDA’s mercury amalgam rule,” says the lengthy petition replete with facts and figures—and worthy of a research project.

The petition presents its case citing several sources, including the World Health Organization (WHO), the European Commission’s Scientific Committee on Emerging and Newly-Identified Health Risks and the Pan American Health Organization (PAHO)

According to the Wall Street Journal last week, FDA Commissioner Dr Scott Gottlieb, in a sweeping regulatory overhaul of Big Tobacco, has cracked down on tobacco companies, demanding that all cigarettes should have such low levels of nicotine so they no longer are considered addictive.

But dental mercury apparently continues to get a free pass.

Charlie Brown, executive director of Consumers for Dental Choice, told IPS that with all the modern mercury-free dental fillings available today, it is inexcusable that FDA remains the world’s chief defender of implanting neurotoxic mercury in children’s mouths – mere centimeters from their developing brains.”

It’s time for FDA to catch up to the European Union and ban amalgam use in children, pregnant women, and breastfeeding mothers,” he added.

Michael Bender, Director, Mercury Policy Project in Vermont, USA, told IPS: “During negotiations, the U.S. stated position was ‘to achieve the phase down, with the goal, the eventual phase out’ of dental amalgam. FDA should stop acting like a rogue agency and follow the US position.”

In its petition, CDC urges the Commissioner to take three key measures to stop amalgam use in children under age 15, pregnant women, and breastfeeding mothers:

Firstly, issue a safety communication warning dentists, parents, and dental consumers against amalgam use in children, pregnant women, and breastfeeding mothers.

Secondly, require manufacturers to distribute patient-labeling that includes warnings against amalgam use in children, pregnant women, and breastfeeding mothers.

Thirdly, develop and implement a public information campaign (including FDA’s website, social media, press releases, and a press conference) to warn dentists, dental associations, parents, and dental consumers against amalgam use in children, pregnant women, and breastfeeding mothers.

The petition also says the 2013 Minamata Convention on Mercury requires nations to “phase down the use of dental amalgam.”

The U.S. government signed and accepted the Minamata Convention on 6 November 2013. FDA’s official support for “change towards use of dental amalgam” and its rejection of “any change away from use of dental amalgam” in its 2009 dental amalgam rule is contrary to the Minamata Convention’s requirement that parties “phase down the use of dental amalgam.”

FDA’s push for phasing up amalgam use has raised major concerns in the international community, says the petition.

The Convention enters into force – and becomes legally binding– on 16 August. On 18 May the 50thnation ratified, and with that threshold reached, the Convention enters into force in 90 days– namely, 16 August. Jamaica was the 71stnation to ratify the convention last week.

Asked for an FDA response, Stephanie Caccomo, Press Officer, Office of Media Affairs & Office of External Affairs, told IPS the FDA has neither promoted the use of dental amalgams nor supported an increase in their use.

FDA serves as the Department of Health and Human Services (HHS) lead representative to the Minamata Convention on Mercury and takes very seriously the Convention’s objective of protecting human health from the possible adverse health effects of mercury exposure, she added.

“The U.S. actively supported the Convention throughout its development and the FDA continues to work closely with the U.S. Department of State on how the United States will implement the treaty obligations.”

She pointed out that the U.S. government is committed to complying with the Convention by taking at least two of the nine specific measures set forth in Part II of Annex A of the Convention with respect to dental amalgam.

Elaborating further, she said in an email message, that dental amalgam contains elemental mercury. It releases low levels of mercury in the form of a vapor that can be inhaled and absorbed by the lungs. High levels of mercury vapor exposure are associated with adverse effects in the brain and the kidneys.

“FDA has reviewed the best available scientific evidence to determine whether the low levels of mercury vapor associated with dental amalgam fillings are a cause for concern. Based on this evidence, FDA considers dental amalgam fillings safe for adults and children ages 6 and above.”

The weight of credible scientific evidence reviewed by FDA does not establish an association between dental amalgam use and adverse health effects in the general population. Clinical studies in adults and children ages 6 and above have found no link between dental amalgam fillings and health problems, she noted.

“The developing neurological systems in fetuses and young children may be more sensitive to the neurotoxic effects of mercury vapor. Very limited to no clinical data is available regarding long-term health outcomes in pregnant women and their developing fetuses, and children under the age of six, including infants who are breastfed. Pregnant women and parents with children under six who are concerned about the absence of clinical data as to long-term health outcomes should talk to their dentist.”

However, the estimated amount of mercury in breast milk attributable to dental amalgam is low and falls well below general levels for oral intake that the Environmental Protection Agency (EPA) considers safe, she added.

“Despite the limited clinical information, FDA concludes that the existing risk information supports a finding that infants are not at risk for adverse health effects from the mercury in breast milk of women exposed to mercury vapor from dental amalgam.”

Some individuals have an allergy or sensitivity to mercury or the other components of dental amalgam (such as silver, copper, or tin). Dental amalgam might cause these individuals to develop oral lesions or other contact reactions.

“If you are allergic to any of the metals in dental amalgam, you should not get amalgam fillings. You can discuss other treatment options with your dentist,” she advised.

To the extent there are any potential risks to health generally associated with the use of dental amalgam, FDA issued a final rule and related guidance document establishing special regulatory controls to mitigate any such risks.

“Moreover, while FDA does not believe additional action is warranted at this time, FDA continues to evaluate the literature on dental amalgam and any other new information it receives in light of the 2010 advisory panel recommendations and will take further action on dental amalgam as warranted,” Caccomo added.

Asked for a response to the FDA statement, Charlie Brown said: “Consumers for Dental Choice’s petition demands that FDA carry out its duty to provide American children the same protection from amalgam’s mercury that the European Union does over there.”

He pointed out that FDA admits repeatedly that no evidence exist that amalgam’s mercury is safe for young children, yet FDA will not stop being the world’s most stubborn defender of implanting mercury into children’s mouths (and bodies).

“FDA must now fish or cut bait. With our petition in its lap, FDA must choose between, on the one hand, doing its duty as a federal agency, and, on the other hand, keeping in place its four-decade-long program of putting profits for pro-mercury dentists ahead of lives of American children,” he declared.

Meanwhile, Consumers for Dental Choice says its campaign goal for Mercury-Free Dentistry is to phase out the use of amalgam, a 50% mercury product — worldwide. The recently concluded draft mercury treaty requires each signing nation to phase down its use of amalgam, and it provides a road map how.

“We aim to: educate consumers about the use of mercury in dentistry so they can make informed decisions; stop dental mercury pollution; protect consumers – especially vulnerable populations such as children and the unborn – from exposure to dental mercury; empower dental workers – dental assistants and hygienists – to protect themselves from mercury in the workplace; and promote access to mercury-free alternatives to amalgam.

The post US Lags Far Behind in Banning Dental Health Hazard appeared first on Inter Press Service.

[chicbamboowear]

US Lags Far Behind in Banning Dental Health Hazard

Environment, Featured, Global, Global Governance, Headlines, Health, Inequity, IPS UN: Inside the Glasshouse, Population, Regional Categories, Sustainability, TerraViva United Nations

Example of mercury use in the healthcare sector. From left to right: Mercury Sphygmomanometer, Dental Amalgam and a Fever Thermometer. Credit: UNDP

UNITED NATIONS, Jul 31 2017 (IPS) – The United States is lagging far behind its Western allies – and perhaps most of the key developing countries – in refusing to act decisively to end a longstanding health and environmental hazard: the use of mercury in dentistry.

The 28-member European Union (EU), with an estimated population of over 510 million people, recently announced its decision to ban amalgam use in children under age 15, pregnant women, and breastfeeding mothers. The ban comes into effect July 2018.

“In sharp contrast, the U.S. government has done nothing to protect these vulnerable populations from exposure to amalgam’s mercury,” says a petition filed by Consumers for Dental Choice (CDC), which has been vigorously campaigning for mercury-free dentistry, since its founding back in 1996.

In Norway and Sweden, dental amalgam is no longer in use, while it is being phased out in Japan, Finland and the Netherlands. In Mauritius and EU nations, it is banned from use on children. Denmark uses dental amalgam for only 5% of restorations and Germany for 10% of restorations.

In Bangladesh, it is to be phased out in 2018, and in India, there is a dental school requirement of eliminating amalgam in favour of alternatives.

In Nigeria, the government has printed and distributed consumer-information brochures while the government of Canada has recommended that all dentists stop its use in children and pregnant women — and those with kidney disorders.

Dental amalgam has been described as a dental filling material used to fill cavities caused by tooth decay. And it is a mixture of metals, consisting of liquid (elemental) mercury and a powdered alloy composed of silver, tin, and copper.

In its petition, addressed to the FDA Commissioner, CDC says the United States – one of the only developed nation with no warnings or restrictions on the use of dental amalgam in children – is the outlier.

“Why are other countries protecting their children while the FDA lets American children be exposed to dental mercury? In order to catch up with other developed nations, the Commissioner must amend FDA’s mercury amalgam rule,” says the lengthy petition replete with facts and figures—and worthy of a research project.

The petition presents its case citing several sources, including the World Health Organization (WHO), the European Commission’s Scientific Committee on Emerging and Newly-Identified Health Risks and the Pan American Health Organization (PAHO)

According to the Wall Street Journal last week, FDA Commissioner Dr Scott Gottlieb, in a sweeping regulatory overhaul of Big Tobacco, has cracked down on tobacco companies, demanding that all cigarettes should have such low levels of nicotine so they no longer are considered addictive.

But dental mercury apparently continues to get a free pass.

Charlie Brown, executive director of Consumers for Dental Choice, told IPS that with all the modern mercury-free dental fillings available today, it is inexcusable that FDA remains the world’s chief defender of implanting neurotoxic mercury in children’s mouths – mere centimeters from their developing brains.”

It’s time for FDA to catch up to the European Union and ban amalgam use in children, pregnant women, and breastfeeding mothers,” he added.

Michael Bender, Director, Mercury Policy Project in Vermont, USA, told IPS: “During negotiations, the U.S. stated position was ‘to achieve the phase down, with the goal, the eventual phase out’ of dental amalgam. FDA should stop acting like a rogue agency and follow the US position.”

In its petition, CDC urges the Commissioner to take three key measures to stop amalgam use in children under age 15, pregnant women, and breastfeeding mothers:

Firstly, issue a safety communication warning dentists, parents, and dental consumers against amalgam use in children, pregnant women, and breastfeeding mothers.

Secondly, require manufacturers to distribute patient-labeling that includes warnings against amalgam use in children, pregnant women, and breastfeeding mothers.

Thirdly, develop and implement a public information campaign (including FDA’s website, social media, press releases, and a press conference) to warn dentists, dental associations, parents, and dental consumers against amalgam use in children, pregnant women, and breastfeeding mothers.

The petition also says the 2013 Minamata Convention on Mercury requires nations to “phase down the use of dental amalgam.”

The U.S. government signed and accepted the Minamata Convention on 6 November 2013. FDA’s official support for “change towards use of dental amalgam” and its rejection of “any change away from use of dental amalgam” in its 2009 dental amalgam rule is contrary to the Minamata Convention’s requirement that parties “phase down the use of dental amalgam.”

FDA’s push for phasing up amalgam use has raised major concerns in the international community, says the petition.

The Convention enters into force – and becomes legally binding– on 16 August. On 18 May the 50thnation ratified, and with that threshold reached, the Convention enters into force in 90 days– namely, 16 August. Jamaica was the 71stnation to ratify the convention last week.

Asked for an FDA response, Stephanie Caccomo, Press Officer, Office of Media Affairs & Office of External Affairs, told IPS the FDA has neither promoted the use of dental amalgams nor supported an increase in their use.

FDA serves as the Department of Health and Human Services (HHS) lead representative to the Minamata Convention on Mercury and takes very seriously the Convention’s objective of protecting human health from the possible adverse health effects of mercury exposure, she added.

“The U.S. actively supported the Convention throughout its development and the FDA continues to work closely with the U.S. Department of State on how the United States will implement the treaty obligations.”

She pointed out that the U.S. government is committed to complying with the Convention by taking at least two of the nine specific measures set forth in Part II of Annex A of the Convention with respect to dental amalgam.

Elaborating further, she said in an email message, that dental amalgam contains elemental mercury. It releases low levels of mercury in the form of a vapor that can be inhaled and absorbed by the lungs. High levels of mercury vapor exposure are associated with adverse effects in the brain and the kidneys.

“FDA has reviewed the best available scientific evidence to determine whether the low levels of mercury vapor associated with dental amalgam fillings are a cause for concern. Based on this evidence, FDA considers dental amalgam fillings safe for adults and children ages 6 and above.”

The weight of credible scientific evidence reviewed by FDA does not establish an association between dental amalgam use and adverse health effects in the general population. Clinical studies in adults and children ages 6 and above have found no link between dental amalgam fillings and health problems, she noted.

“The developing neurological systems in fetuses and young children may be more sensitive to the neurotoxic effects of mercury vapor. Very limited to no clinical data is available regarding long-term health outcomes in pregnant women and their developing fetuses, and children under the age of six, including infants who are breastfed. Pregnant women and parents with children under six who are concerned about the absence of clinical data as to long-term health outcomes should talk to their dentist.”

However, the estimated amount of mercury in breast milk attributable to dental amalgam is low and falls well below general levels for oral intake that the Environmental Protection Agency (EPA) considers safe, she added.

“Despite the limited clinical information, FDA concludes that the existing risk information supports a finding that infants are not at risk for adverse health effects from the mercury in breast milk of women exposed to mercury vapor from dental amalgam.”

Some individuals have an allergy or sensitivity to mercury or the other components of dental amalgam (such as silver, copper, or tin). Dental amalgam might cause these individuals to develop oral lesions or other contact reactions.

“If you are allergic to any of the metals in dental amalgam, you should not get amalgam fillings. You can discuss other treatment options with your dentist,” she advised.

To the extent there are any potential risks to health generally associated with the use of dental amalgam, FDA issued a final rule and related guidance document establishing special regulatory controls to mitigate any such risks.

“Moreover, while FDA does not believe additional action is warranted at this time, FDA continues to evaluate the literature on dental amalgam and any other new information it receives in light of the 2010 advisory panel recommendations and will take further action on dental amalgam as warranted,” Caccomo added.

Asked for a response to the FDA statement, Charlie Brown said: “Consumers for Dental Choice’s petition demands that FDA carry out its duty to provide American children the same protection from amalgam’s mercury that the European Union does over there.”

He pointed out that FDA admits repeatedly that no evidence exist that amalgam’s mercury is safe for young children, yet FDA will not stop being the world’s most stubborn defender of implanting mercury into children’s mouths (and bodies).

“FDA must now fish or cut bait. With our petition in its lap, FDA must choose between, on the one hand, doing its duty as a federal agency, and, on the other hand, keeping in place its four-decade-long program of putting profits for pro-mercury dentists ahead of lives of American children,” he declared.

Meanwhile, Consumers for Dental Choice says its campaign goal for Mercury-Free Dentistry is to phase out the use of amalgam, a 50% mercury product — worldwide. The recently concluded draft mercury treaty requires each signing nation to phase down its use of amalgam, and it provides a road map how.

“We aim to: educate consumers about the use of mercury in dentistry so they can make informed decisions; stop dental mercury pollution; protect consumers – especially vulnerable populations such as children and the unborn – from exposure to dental mercury; empower dental workers – dental assistants and hygienists – to protect themselves from mercury in the workplace; and promote access to mercury-free alternatives to amalgam.

Sponsored

Ellen Shocks LGBT Community & Confirms She Is Moving On

Many knew what Ellen’s plan was, but no one expected it to leak like this…. Learn More Sponsored by Celebritique

Report ad

Source Article

The post US Lags Far Behind in Banning Dental Health Hazard appeared first on CHICBAMBOOWEAR.

Learn More: http://www.chicbamboowear.com/us-lags-far-behind-in-banning-dental-health-hazard/

[medserg1501]

Best Oncology Treatment in Mauritius

Mauritius has developed a reputation for offering the best oncology treatment, providing comprehensive cancer care that includes diagnosis, surgery, radiation, and chemotherapy. Specialized cancer treatment centers in Mauritius are staffed with experienced oncologists who are skilled in treating various types of cancers, including breast, lung, prostate, and colorectal cancers. These centers use advanced equipment for radiation therapy and modern chemotherapy protocols, ensuring that patients receive effective treatment.

Oncology care in Mauritius is further supported by diagnostic imaging, biopsy services, and palliative care options that help manage symptoms and improve quality of life. By partnering with MedSerg, patients seeking the best oncology treatment in Mauritius can access personalized, evidence-based cancer care that includes guidance on preventive screenings and survivorship planning.

[medserg1501]

 Best Neurology Treatment in Mauritius

Mauritius offers comprehensive neurology care for conditions such as stroke, epilepsy, Parkinson’s disease, and multiple sclerosis. Neurology hospitals in Mauritius are equipped with cutting-edge diagnostic tools and staffed by experienced neurologists who use advanced therapies, including neurorehabilitation and minimally invasive neurosurgery. These facilities provide a range of treatments, from early diagnosis to long-term management and post-stroke rehabilitation, ensuring a holistic approach to neurological care. Mauritius’ top neurologists adopt an individualized treatment approach, focusing on both patient comfort and effective symptom management. The combination of expertise, innovative treatments, and dedicated follow-up care makes Mauritius an ideal location for neurology treatment.

[medserg1501]

Best Oncology Treatment in Mauritius

Best Oncology Treatment in Mauritius is home to advanced oncology centers that provide high-quality cancer treatment, including chemotherapy, radiotherapy, immunotherapy, and surgical oncology. Specialized teams in Mauritius offer targeted treatments and personalized care plans, helping patients manage cancer effectively. For complex cases or patients seeking additional treatment options, MedSerg connects Mauritius patients to India’s leading cancer hospitals, where they can access state-of-the-art treatments and high survival outcomes, all within comprehensive oncology treatment packages.

[medserg1501]

Best Cardiology Treatment in Mauritius

Best Cardiology Treatment in Mauritius for various heart conditions. Equipped with state-of-the-art medical technology, hospitals in Mauritius provide advanced diagnostic and treatment procedures, including angioplasty, heart bypass surgery, and pacemaker implantation. The country's cardiologists are well-trained and experienced, capable of handling complex cardiovascular issues. For patients seeking routine heart check-ups or specialized treatment, the best cardiology centers in Mauritius offer comprehensive services. However, for those looking for more affordable or specialized treatment options, medical tourism to India is also popular. Indian hospitals are renowned for their cardiac care, providing world-class treatment at a fraction of the cost. MedSerg, a leading medical tourism company, helps connect Mauritian patients with top Indian hospitals for specialized cardiology care, ensuring patients receive the best outcomes.

[medserg1501]

Best Cardiology Treatment in Mauritius

It offers quality and Best Cardiology Treatment in Mauritius for patients suffering from heart conditions such as coronary artery disease, heart failure, and arrhythmias. With advanced diagnostic tools and modern treatment methods, cardiology specialists in Mauritius provide services such as angioplasty, pacemaker implants, and open-heart surgery. However, for complex procedures like heart transplants or valve replacements, patients may seek treatment abroad. MedSerg helps Mauritius patients access the best cardiology hospitals in India, offering cutting-edge treatments at affordable costs.

[medserg1501]

Best Cardiology Treatment in Mauritius

Mauritius offers some of the best cardiology treatment options in the region, making it an ideal destination for patients seeking high-quality cardiac care. Leading hospitals, such as Apollo Bramwell and Wellkin Hospital, are equipped with state-of-the-art technology and provide a comprehensive range of cardiology services. These facilities offer advanced diagnostic procedures, including echocardiograms, stress tests, and angiograms, enabling accurate assessments of heart health. The experienced cardiologists in Mauritius are highly trained in managing a variety of cardiovascular conditions, including coronary artery disease, arrhythmias, and hypertension. Personalized treatment plans are crafted to address each patient's unique needs, combining lifestyle modifications, medication, and interventional procedures when necessary. Additionally, the emphasis on preventive care helps patients reduce their risk factors and maintain optimal heart health. With a focus on quality and patient-centered care, Mauritius stands out as a top choice for those in need of effective cardiology treatment.

[medserg1501]

Best Cardiology Treatment in Mauritius

Mauritius offers some of the best cardiology treatment options in the region, with advanced healthcare facilities equipped to handle a variety of cardiovascular conditions. Hospitals like the Apollo Bramwell Hospital and the Wellkin Hospital provide comprehensive cardiology services, including diagnostic tests, interventional procedures, and cardiac rehabilitation programs. The cardiology specialists in Mauritius are highly trained and experienced in managing conditions such as heart disease, arrhythmias, and hypertension. Patients benefit from personalized treatment plans tailored to their specific needs, ensuring optimal care. With a focus on both prevention and intervention, Mauritius stands out as a destination for effective cardiology treatment.

[medserg1501]

Best Cardiology Treatment in Mauritius

The best cardiology treatment in Mauritius is provided by leading healthcare institutions equipped with advanced technology and specialized cardiac care units. Mauritius has several top-tier hospitals and cardiac centers offering comprehensive care for a wide range of heart conditions, including coronary artery disease, heart failure, and congenital heart defects. These facilities are equipped with state-of-the-art diagnostic tools such as 3D echocardiography, cardiac catheterization labs, and advanced imaging technology to ensure accurate diagnosis and effective treatment.

Renowned cardiologists in Mauritius, along with a multidisciplinary team of healthcare professionals, provide patient-centric care through a range of interventional and surgical procedures, such as angioplasty, bypass surgery, and heart valve repair or replacement. Hospitals like Apollo Bramwell, Wellkin Hospital, and Fortis Clinique Darné are known for their high-quality cardiac care and focus on patient safety. The best cardiology treatment in Mauritius ensures a holistic approach to patient management, including cardiac rehabilitation and lifestyle modification support for long-term heart health.

Mauritius has become a hub for specialized cardiac care, offering international patients affordable treatment options without compromising on quality. The availability of highly skilled cardiologists, modern facilities, and personalized care plans makes the island a favorable destination for cardiac treatments.

[medserg1501]

Best Cardiology Treatment in Mauritius

Mauritius offers quality cardiology treatment with access to skilled cardiologists and advanced healthcare facilities. Leading hospitals such as Wellkin Hospital and Apollo Bramwell Hospital provide state-of-the-art diagnostic services, interventional cardiology, and surgical treatments for various heart conditions. Treatments include angioplasty, coronary artery bypass grafting (CABG), and heart valve replacement surgeries. The medical staff is highly trained, ensuring that patients receive the best care for both routine and complex heart conditions. For patients requiring specialized procedures, partnerships with Indian hospitals, like Medanta and Apollo Hospitals, also ensure access to top-notch cardiology services.

[medserg1501]

Best Neurology Treatment in Mauritius

Mauritius has highly developed neurology departments that cater to a range of neurological disorders including epilepsy, stroke, Parkinson’s disease, and brain injuries. Fortis Clinique Darné and Wellkin Hospital are renowned for their expertise in diagnosing and treating complex neurological conditions. These hospitals are equipped with cutting-edge diagnostic tools like MRIs and CT scans, offering both surgical and non-surgical interventions. MedSerg connects patients with leading neurologists in Mauritius for comprehensive care and long-term management of neurological conditions.

[medserg1501]

Neurology Treatment in India for Mauritius Patients

India has emerged as a leading destination for neurology treatment for Mauritius patients, providing advanced medical care at competitive prices. With a range of neurological disorders, including stroke, epilepsy, multiple sclerosis, and neurodegenerative diseases, Indian hospitals offer comprehensive treatment options that include advanced diagnostics, medications, and specialized surgical procedures. 

Renowned neurologists and neurosurgeons in India use state-of-the-art technology, such as MRI, CT scans, and neuro-electrophysiological assessments, to diagnose and treat neurological conditions effectively. Procedures such as minimally invasive brain surgery, deep brain stimulation, and endoscopic spine surgery are performed in leading hospitals, ensuring high standards of care and successful outcomes.

Indian hospitals also emphasize a multidisciplinary approach, often involving physiotherapists, psychologists, and rehabilitation specialists to provide holistic care for neurology patients. Many institutions, including Apollo Hospitals, Fortis Healthcare, and Max Healthcare, have dedicated international patient services, offering support for visa arrangements, accommodation, and language translation, making the entire process easier for patients traveling from Mauritius.

Through MedSerg, Mauritius patients can explore and connect with top neurology specialists and treatment facilities in India, ensuring access to high-quality care and innovative treatment options tailored to their specific needs.